Scienture Holdings, Inc. (SCNX): Nasdaq/NYSE listing notice — TRxADE HEALTH receives Nasdaq delisting notice for failure to meet $2.5M equity minimum; hearing requested

Scienture Holdings, Inc.

Nasdaq notified company on Jan 30, 2023 of failure to meet $2.5M min stockholders' equity after extension granted Oct 17, 2022.
Company filed hearing request on Feb 6, 2023 with Nasdaq Hearings Panel; delisting stayed pending hearing outcome.
At hearing, company will propose plan to regain compliance; no guarantee of acceptance or eventual relisting.
If delisted, trading liquidity and ability to raise capital could be materially impaired.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Scienture Holdings, Inc. received a nasdaq delisting notice notice regarding stockholders equity.

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity

Exact text from the filing

February 6, 2023, the Company submitted a hearing request to the Nasdaq Hearings Panel (the “ Panel ”), which request will stay any delisting action by the Staff at least until the hearing process concludes and any extension granted by the Panel expires. At the Panel hearing, the Company intends to present a plan to regain compliance with the minimum stockholders’ equity requirement. In the interim, the Company’s common stock will continue to trade on Nasdaq under the symbol “ MEDS ” at least pending the ultimate conclusion of the hearing process. There can be no assurance that the Company’s p

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Scienture Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-003740

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.